JP2005510503A5 - - Google Patents

Download PDF

Info

Publication number
JP2005510503A5
JP2005510503A5 JP2003538151A JP2003538151A JP2005510503A5 JP 2005510503 A5 JP2005510503 A5 JP 2005510503A5 JP 2003538151 A JP2003538151 A JP 2003538151A JP 2003538151 A JP2003538151 A JP 2003538151A JP 2005510503 A5 JP2005510503 A5 JP 2005510503A5
Authority
JP
Japan
Prior art keywords
hydrogen
alkyl
hydroxy
aryl
disease
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2003538151A
Other languages
English (en)
Japanese (ja)
Other versions
JP2005510503A (ja
Filing date
Publication date
Priority claimed from AUPR8464A external-priority patent/AUPR846401A0/en
Application filed filed Critical
Publication of JP2005510503A publication Critical patent/JP2005510503A/ja
Publication of JP2005510503A5 publication Critical patent/JP2005510503A5/ja
Pending legal-status Critical Current

Links

JP2003538151A 2001-10-25 2002-10-25 6−ヒドロキシイソフラボン、誘導体及びそれを含む薬剤 Pending JP2005510503A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
AUPR8464A AUPR846401A0 (en) 2001-10-25 2001-10-25 6-Hydroxy isoflavones, derivatives and medicaments involving same
PCT/AU2002/001442 WO2003035635A1 (en) 2001-10-25 2002-10-25 6-hydroxy isoflavones, derivatives and medicaments involving same

Publications (2)

Publication Number Publication Date
JP2005510503A JP2005510503A (ja) 2005-04-21
JP2005510503A5 true JP2005510503A5 (enExample) 2005-12-22

Family

ID=3832286

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2003538151A Pending JP2005510503A (ja) 2001-10-25 2002-10-25 6−ヒドロキシイソフラボン、誘導体及びそれを含む薬剤

Country Status (11)

Country Link
US (1) US20050049424A1 (enExample)
EP (1) EP1448542A4 (enExample)
JP (1) JP2005510503A (enExample)
CN (1) CN1575289A (enExample)
AU (1) AUPR846401A0 (enExample)
CA (1) CA2464593A1 (enExample)
HU (1) HUP0401648A3 (enExample)
IL (1) IL161517A0 (enExample)
MX (1) MXPA04003874A (enExample)
NO (1) NO20042084L (enExample)
WO (1) WO2003035635A1 (enExample)

Families Citing this family (37)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
USRE40792E1 (en) 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
AUPP260798A0 (en) * 1998-03-26 1998-04-23 Novogen Research Pty Ltd Treatment of medical related conditions with isoflavone containing extracts of clover
US20040072765A1 (en) * 1999-04-28 2004-04-15 Novogen Research Pty Ltd. Cardiovascular and bone treatment using isoflavones
AUPQ520300A0 (en) * 2000-01-21 2000-02-17 Novogen Research Pty Ltd Food product and process
EP2407462B1 (en) 2004-09-21 2014-07-30 Marshall Edwards, Inc. Substituted chroman derivatives, medicaments and use in therapy
US8080675B2 (en) 2004-09-21 2011-12-20 Marshall Edwards, Inc. Chroman derivatives, medicaments and use in therapy
WO2006099193A2 (en) * 2005-03-11 2006-09-21 The Regents Of The University Of Michigan Chromen-4-one inhibitors of anti-apoptotic bcl-2 family members and the uses thereof
ATE496921T1 (de) * 2005-03-24 2011-02-15 Novogen Res Pty Ltd Isoflavonoiddimere
TWI366565B (en) 2007-06-06 2012-06-21 Otsuka Pharma Co Ltd Quinolone compound and pharmaceutical composition
WO2009049214A2 (en) * 2007-10-12 2009-04-16 Northwestern University Inhibition and treatment of prostate cancer metastasis
HRP20161447T1 (hr) * 2008-07-31 2016-12-16 Sigma-Tau Industrie Farmaceutiche Riunite S.P.A. Pripravak koji sadrži ekstrakt zelenog čaja i ekstrakt nara, namijenjen upotrebi u sprječavanju ili usporavanju napredovanja raka prostate
WO2010042933A2 (en) 2008-10-10 2010-04-15 Northwestern University Inhibition and treatment of prostate cancer metastasis
TWI492943B (zh) 2008-12-05 2015-07-21 大塚製藥股份有限公司 喹啉酮化合物及藥學組成物(二)
IN2012DN02624A (enExample) * 2009-10-09 2015-05-22 Nestec Sa
WO2011156889A1 (en) * 2010-06-14 2011-12-22 Trt Pharma Inc. Novel modulators of nrf2 and uses thereof
EP2635121B1 (en) 2010-11-01 2020-01-08 MEI Pharma, Inc. Isoflavonoid compounds and methods for the treatment of cancer
WO2012066330A1 (en) 2010-11-17 2012-05-24 Heptares Therapeutics Limited Compounds useful as a2a receptor inhibitors
HUE054998T2 (hu) 2015-02-02 2021-10-28 Mei Pharma Inc Kombinációs terápiák emlõrák kezelésében való alkalmazásra
CN104829580B (zh) * 2015-04-11 2017-11-24 云南中烟工业有限责任公司 烟草所含的异黄酮类化合物及其制备方法和应用
US9718799B2 (en) 2015-05-11 2017-08-01 University Of Kentucky Research Foundation 3-aryl-4H-chromene-4-ones as antineoplastic agents for the treatment of cancer
JP6099024B2 (ja) * 2015-05-18 2017-03-22 株式会社東洋新薬 ホスホジエステラーゼ3阻害剤
CA3058492A1 (en) 2016-04-06 2017-10-12 Noxopharm Limited Radiotherapy improvements
JP2019513828A (ja) 2016-04-06 2019-05-30 ノクソファーム リミティド 改善された薬物動態を有するイソフラボノイド組成物
CN107441079B (zh) * 2017-08-22 2021-03-26 四川省中医药科学院 一种治疗心脑血管疾病的药物及其制备方法和用途
UA127357C2 (uk) 2018-04-18 2023-07-26 Констеллатіон Фармацеутікалс, Інк. Модулятори метилмодифікуючих ферментів, композиції та їх використання
EP3797108B1 (en) 2018-05-21 2022-07-20 Constellation Pharmaceuticals, Inc. Modulators of methyl modifying enzymes, compositions and uses thereof
KR102527205B1 (ko) * 2018-08-31 2023-05-03 서울대학교산학협력단 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물
WO2020045856A1 (ko) * 2018-08-31 2020-03-05 서울대학교 산학협력단 신규한 HIF-1α 억제제, 이의 제조방법 및 이를 유효성분으로 함유하는 신생혈관 관련 안질환의 예방 또는 치료용 약학적 조성물
WO2020051644A1 (en) * 2018-09-13 2020-03-19 Norbio No. 2 Pty Ltd Treatment of peripheral nervous tissue inflammation
CN109925308A (zh) * 2018-12-29 2019-06-25 广东宏盈科技有限公司 异黄酮在制备治疗眼底黄斑病变的药物中的应用
MD4003532T2 (ro) 2019-07-24 2025-01-31 Constellation Pharmaceuticals Inc Forme cristaline de 7-clor-2-(4-(3-metoxiazetidin-1-il)ciclohexil)-2,4-dimetil-N-((6-metil-4-(metiltio)-2-oxo-1,2-dihidropiridin-3-il)metil)benzo[d][1,3]dioxol-5-carboxamidă
CN110590738B (zh) * 2019-08-27 2022-03-01 温州大学 一种3,6-二甲基-1-仲胺基-7-氰基-8-羟基异喹啉类化合物的合成方法
AU2021247415A1 (en) 2020-03-30 2022-09-29 Noxopharm Limited Methods for the treatment of inflammation associated with infection
WO2021195698A1 (en) * 2020-03-30 2021-10-07 Noxopharm Limited Methods for the treatment of inflammation associated with infection
CN117384124B (zh) * 2022-07-04 2025-08-01 安徽中医药大学 Hdac抑制剂、组合物及其应用
WO2025023252A1 (ja) * 2023-07-24 2025-01-30 国立大学法人 大分大学 抗酸化化合物
CN118373794B (zh) * 2024-04-17 2025-08-29 中国中医科学院中药研究所 一种异黄酮类化合物及其制备方法和在制药中的应用

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4264509A (en) * 1977-06-08 1981-04-28 Z-L Limited Partnership Isoflavones and related compounds, methods of preparing and using and antioxidant compositions containing same
GB8626344D0 (en) * 1986-11-04 1986-12-03 Zyma Sa Bicyclic compounds
USRE40792E1 (en) * 1992-05-19 2009-06-23 Novogen Research Pty Ltd Health supplements containing phyto-oestrogens, analogues or metabolites thereof
AUPO203996A0 (en) * 1996-08-30 1996-09-26 Novogen Research Pty Ltd Therapeutic uses
GB9621757D0 (en) * 1996-10-18 1996-12-11 Ciba Geigy Ag Phenyl-substituted bicyclic heterocyclyl derivatives and their use
US5733926A (en) * 1996-12-13 1998-03-31 Gorbach; Sherwood L. Isoflavonoids for treatment and prevention of alzheimer dementia and reduced cognitive functions
US6146668A (en) * 1997-04-28 2000-11-14 Novogen, Inc. Preparation of isoflavones from legumes
US6340703B1 (en) * 1997-05-01 2002-01-22 Novogen, Inc. Treatment or prevention of osteoporosis
WO1999049862A1 (en) * 1998-03-30 1999-10-07 The University Of Mississippi Isoflavones for treating giardiasis and malaria
AUPQ008299A0 (en) * 1999-04-30 1999-05-27 G.J. Consultants Pty Ltd Isoflavone metabolites
FI20001593A7 (fi) * 2000-07-03 2002-01-04 Orion Yhtymo Oyj Comt-entsyymiõ inhiboivaa aktiivisuutta omaavia kumariinijohdannaisia
JP4256679B2 (ja) * 2001-03-16 2009-04-22 ノボゲン リサーチ ピーティーワイ リミテッド 再狭窄の治療方法

Similar Documents

Publication Publication Date Title
JP2005510503A5 (enExample)
JP2010520889A5 (enExample)
MA31504B1 (fr) Acides benzoylamino-indan-2-carboxyliques substitues et composes apparentes
US20250352501A1 (en) Methods Of Treatment Of Inflammation Related Conditions Using Pluripotent Anti-inflammatory And Metabolic Modulators
WO2002016333A3 (en) Thioflavin derivatives and their use in diagnosis and theraphy of alzheimer's disease
CN1575289A (zh) 6-羟基异黄酮、及其衍生物和相关药物
JP2015535247A5 (enExample)
IL157750A (en) Isoflavones dimers, their preparation process and pharmaceutical preparations containing them
MA31923B1 (fr) Composés de 1,2,4-oxadiazole pour le traitement de maladies auto-immunes
JP2010522711A5 (enExample)
US20230346728A1 (en) Methods of Treatment of Inflammation Related Conditions Using Pluripotent Anti-Inflammatory and Metabolic Modulators
JP7600131B2 (ja) 神経系疾患の予防または治療用薬学的組成物
JP2010510216A5 (enExample)
US10906864B2 (en) Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDS) and methods of treating inflammation related conditions
JP2021127289A (ja) 縮合ピリミジン誘導体
US20200147017A1 (en) Methods of Treatment of inflammation related conditions using pluripotent anti-inflammatory and metabolic Modulators
WO2013064714A1 (es) Fármacos inhibidores de p38 y aplicaciones
WO1998050025A1 (en) Preventives/remedies for arteriosclerosis
JP2024525792A (ja) 治療に使用するための6H-イミダゾ[1,2-a]ピロロ[2,3-e]ピリジン誘導体
JPWO2006132438A1 (ja) 1,3−ベンゾチアジノン誘導体およびその用途
US7345079B2 (en) Treatment of disorder related to low cyclic GMP levels
AU2017444990B2 (en) Nitroalkene non steroidal anti-inflammatory drugs (NA-NSAIDs) and methods of treating inflammation related conditions
JP2024525791A (ja) 治療に使用するためのイミダゾ[1,2-b][1,2,4]トリアゾール誘導体
JP2005060311A (ja) N−(ベンゾイル)アミノ酸誘導体を有効成分とするニューロパシー性疼痛治療剤
JP2004035484A (ja) シクロヘキサンジアミン誘導体